|1.||Coy, David H: 4 articles (01/2011 - 07/2004)|
|2.||Fuselier, Joseph A: 3 articles (01/2008 - 07/2004)|
|3.||Sun, Li-Chun: 2 articles (01/2011 - 01/2008)|
|4.||Mackey, L Vienna: 1 article (01/2008)|
|5.||Luo, Jing: 1 article (01/2008)|
|6.||Drouant, George: 1 article (04/2005)|
|7.||Peyman, Gholam A: 1 article (04/2005)|
|8.||Oner, Hakan: 1 article (04/2005)|
|9.||Bezerra, Yanno: 1 article (04/2005)|
|10.||Sun, Lichun: 1 article (07/2004)|
01/01/2011 - "For instance, the CPT-SST conjugate JF-10-81, in which CPT is coupled to the N-terminus of a SSTR2-specific SST analog (JF-07-69), had wide ranging anti-tumor and anti-angiogenic ability. "
01/01/2008 - "Also, JF-10-81 was used to treat highly invasive PC-3 tumors where s.c. "
01/01/2008 - "SSTR-overexpressing BON tumors were unfortunately relatively CPT-insensitive in vitro, however, JF-10-81 again exhibited in vivo potency presumably by specifically increasing CPT concentrations inside the tumor cells so that the inhibition rate for JF-10-81 was 85%. "
07/01/2004 - "Both cytotoxic conjugates significantly inhibited growth of SSTR2-specific pancreatic and SCLC tumors, but JF-10-81 did not significantly affect PC-3 tumor growth. "
07/01/2004 - "CA20948 tumors, known to overexpress SSTR2 and grown in Lewis rats, were treated, respectively, with nontoxic 400 nmol/kg intraperitoneal (i.p.) doses of JF-10-71 or JF-10-81. "
07/01/2004 - "Two CPT-SSA conjugates, JF-10-71 and JF-10-81, containing a chemically adjustable release-rate carbamate linker, have been reported previously by us to potently inhibit growth of human neuroblastoma IMR32 cells overexpressing somatostatin receptor type II (SSTR2) but are stable under buffer incubation conditions or in rat plasma. "
01/01/2008 - "JF-10-81 was found to significantly inhibit growth of these SSTR-positive tumors, resulting in 87% tumor reduction in neuroblastoma IMR32 and 97% in leukemia MOLT-4 bearing animals, even inducing regression of CFPAC-1 tumors. "
01/01/2008 - "JF-10-81 was tested for its inhibitory activity against the growth of human tumors which included neuroblastoma (IMR32), pancreatic cancer (CFPAC-1), leukemia (MOLT-4), pancreatic carcinoid (BON) and prostate cancer (PC-3). "
|4.||Prostatic Neoplasms (Prostate Cancer)
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
|1.||Somatostatin Receptors (Somatostatin Receptor)